| Total (n = 263) | GO (n=219) | No-GO (n=44) | P-value |
---|---|---|---|---|
Demographics | Â | Â | Â | Â |
Age, mean (SD) years | 46.9 (10.3) | 46.9 (10.4) | 46.8 (10.1) | 0.981†|
Gender (female), n (%) | 215 (81.7) | 181 (82.6%) | 34 (77.3%) | 0.399§ |
Disease characteristics | Â | Â | Â | Â |
Diagnosis, n (%) | Â | Â | Â | Â |
EM CM | 32 (12.2) 231 (87.8) | 30 (93.8%) 189 (81.8%) | 2 (6.2%) 42 (18.2%) | 0.056§ |
Duration of migraine disease, mean (SD) years | 25.4 (13.5) | 25.9 (13.2) | 22.8 (14.6) | 0.118‡ |
Chronification time*, mean (SD) years | 9.7 (8.5) | 9.8 (8.6) | 9.3 (8.3) | 0.956‡ |
Aura, n (%) | 75 (28.5) | 60 (27.4%) | 15 (34.1%) | 0.364§ |
MHD, mean (SD), d/mo MMD, mean (SD), d/mo Headache pain intensity, mean (SD), 0-3 score | 22.2 (6.8) 16.7 (7.0) 1.59 (0.56) | 21.5 (6.7) 15.9 (6.9) 1.53 (0.55) | 25.4 (5.8) 20.5 (6.4) 1.90 (0.50) | <0.001‡ <0.001‡ <0.001†|
Preventive treatment | Â | Â | Â | Â |
CGRP-mAb Treatment, n (%) | Â | Â | Â | Â |
Erenumab 140 mg Galcanezumab 120 mg | 164 (62.4) 99 (37.6) | 143 (87.2%) 76 (76.8%) | 21 (12.8%) 23 (23.2%) | 0.072§ |
Concomitant preventive treatment, n (%) | 176 (66.9%) | 136 (62.1%) | 40 (90.9%) | <0.001§ |
Prior preventive classes failures, median [IQR] | 4.0 [1.0] | 4.0 [1.0] | 4.0 [1.2] | 0.448‡ |
Acute medication | Â | Â | Â | Â |
Acute medication frequency, mean (SD), d/mo | 15.5 (8.6) | 14.8 (8.1) | 19.1 (9.8) | 0.008‡ |
Acute medication burden, mean (SD), p/mo | 21.2 (13.3) | 20.7 (13.0) | 24.0 (14.3) | <0.001‡ |
Medication overuse, n (%) | 180 (68.4) | 148 (67.6%) | 32 (72.7%) | 0.486§ |
Migraine-related clinical burden (PROMs) | Â | Â | Â | Â |
Disability (MIDAS), median [IQR] | 59.0 [81.5] | 57.0 [80.0] | 78.5 [152.5] | 0.008‡ |
Headache-related impact (HIT-6), mean (SD) | 67.7 (24.0) | 67.9 (25.8) | 67.0 (11.1) | 0.078‡ |
Quality of life (MSQT), mean (SD) | 32.8 (17.2) | 34.1 (16.7) | 26.4 (18.4) | 0.004‡ |
Anxiety (BAI), median [IQR] | 19.0 [22.0] | 18.0 [20.0] | 29.5 [24.0] | 0.001‡ |
Depression (BDI-II), median [IQR] | 13.0 [17.0] | 12.0 [17.0] | 18.2 [15.2] | 0.004‡ |
Cognitive impairment (MigScog), mean (SD) | 9.3 (5.0) | 9.2 (5.1) | 10.0 (4.7) | 0.230‡ |